Receptos to Present at JMP Securities Healthcare Conference
SAN DIEGO, July 3, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its Chief Financial Officer, Graham Cooper, will be presenting at the 8th Annual JMP Securities Healthcare Conference at the St. Regis Hotel in New York City. The presentation is scheduled for Wednesday, July 10, 2013 at 10:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com . A replay will be available for 7 days after the event.
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708 firstname.lastname@example.org
Source: Receptos, Inc. 2013 GlobeNewswire, Inc.